The vaccine under trials by Europe based biopharmaceutical AstraZeneca Plc. (LON: AZN) and Oxford University has raised hopes of a suitable vaccine against the deadly COVID-19 vaccine after the company said experimental vaccines produces an immune response in both young and old adults.
The vaccine is said to be triggering lower adverse responses among older people. The company was happy with such results since this is a ray of hope for the deadly virus which has so far killed over a million people around the world.
“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher,” said the spokesperson of AstraZeneca.
This news is encouraging due to the fact that elderly people will get an immune response from the vaccine because the immune system of an individual weakens as they get old.
The developed vaccine goes by the technical name AZD1222, the spokesperson added these results are evidence for the safety and immunogenicity of the vaccine.
This vaccine is being seeing as a front runner in the race to find a suitable vaccine against the deadly virus. Experts are betting that it will be the first one to secure regulatory approval in the world.
